AI Follow-Up to Assess Liver Cancer Risk in Hepatitis B Patients
Tests an AI follow-up system for adults with hepatitis B-related liver cirrhosis.
Plain-language title generated from the registry record
Registry title: Risk Assessment for HBV-Related Liver Cancer
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 30 to 75 who have hepatitis B and a higher chance of liver cancer. It tests an AI follow-up system for early detection.
- Age
- 30 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Positive for hepatitis B surface antigen, plus at least one of these: liver cirrhosis on imaging, type II diabetes, family history of liver cirrhosis or liver cancer, long-term alcohol use, liver fibrosis score F3 or above, or Fibroscan value of 8.0kPa or more.
- Biomarker or test result
- Hepatitis B surface antigen must be positive.
Main reasons for not taking part
- Diagnosed with a malignant tumor
- Had a liver transplant
- Infected with HIV
- Expected survival of less than 1 year
- Marked organ dysfunction (heart, brain, kidney, lung, endocrine system, blood) or psychiatric illness
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 75 years old?
Source: NCT07160946, who can take part
Where in China
- Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, ChinaContact: Bingliang Prof. LinTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT07160946
- Record updated
- 8 September 2025
- Original description
Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.Read full original descriptionShow less
Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion
Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.
Inclusion: (a).Positive for Hepatitis B surface antigen; (b).Ultrasound/CT/MR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis/ liver cancer; (e). Long term alcohol consumption history (>5 years), equivalent to alcohol consumption of ≥ 40g/d for males and ≥ 20g/d for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.
Exclusion: (a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time<1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.